Odyssey Health closes exclusive global distribution deal for BreastCheck non-invasive breast test

Odyssey Health, Inc.

Closed sub-license with NeuRX Health granting subsidiary Odyssey Medical Devices exclusive worldwide marketing and distribution rights for BreastCheck.
BreastCheck is a non-invasive, 15-minute test for breast abnormalities, registered with FDA, EU, and UK regulators.
Global breast cancer screening market estimated at $26B; commercial sales expected to begin in H2 2026.
CEO Michael Redmond says agreement provides clear pathway to near-term revenue and supports growth strategy.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Odyssey Health, Inc. entered into Master Technology and Sub-license Agreement with NeuRX Health, Inc. (effective 2025-10-14).

Action: entry
Agreement: license
Counterparty: NeuRX Health, Inc.
Effective: 2025-10-14

Exact text from the filing

On April 21, 2026, Odyssey Health, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) successfully closed the Master Technology and Sub-license Agreement (the “ Agreement ”) with NeuRX Health, Inc. (“ NeuRX ”) which was entered into on October 14, 2025

View on SEC.gov

Browse all material agreements →

Odyssey Health, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-003205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.